Abstract:Rationale: Pulmonary arterial hypertension (PAH) is an enigmatic and morbid disease where insights are emerging regarding genetic susceptibility. Genome-wide Association Studies (GWAS) have identified SOX17 as the most significant PAH-associated genomic locus. The allele of tag SNP in this locus is associated with 1.8-fold higher PAH risk. It has been challenging to define the mechanisms underlying the contribution of the PAH-associated functional SNPs (fSNPs) to pathogenesis of the disease. Methods: We developed a post-GWAS functional genomics strategy to define the causative fSNPs and identify the associated biological mechanisms. This analysis includes Reel-seq (Regulatory element-sequencing), an EMSA-based high-throughput technique to identify fSNPs in a synthetic DNA library containing PAH-associated SNPs; SDCP-MS (SNP-specific DNA competition pulldown-mass spectrometry) to identify proteins that specifically bind to fSNPs; and AIDP-Wb (allele-imbalanced DNA pulldown-Western blot) to show allele-imbalanced binding of these proteins to fSNPs. The regulation of risk gene expression by these fSNP-binding proteins and their pathogenicity were determined in human pulmonary arterial endothelial cells (PAECs) and confirmed in PAH animal models and patients. Results: By using high-throughput Reel-seq and subsequent validation with EMSA, intergenic SNP rs4738801 in SOX17 locus was identified as a fSNP from a library containing 254 PAH-associated haplotype SNPs. This fSNP resides in a remote upstream enhancer region of SOX17, an endothelial effector increasingly associated with PAH pathogenesis. Using SDCP-MS and AIDP-Wb, we found that the transcription factor FUBP1 binds to rs4738801 risk allele C with lower affinity than non-risk allele G, resulting in a decrease in SOX17 expression. FUBP1 and target gene SOX17 controlled PAH-associated pathophenotypes in PAECs, including proliferation, apoptosis, and angiogenesis. Downregulated by the major acquired PAH trigger hypoxia, FUBP1 and SOX17 were decreased in lungs and pulmonary ECs isolated from PAH patients and mouse models. A 3.77-fold enrichment of fSNP rs4738801 risk allele C was found in patients with PAH induced by hypoxia, but not in PAH associated with connective tissue disease or congenital heart disease. Conclusions: FUBP1 controls SOX17 expression via allele-specific binding to PAH-associated fSNP rs4738801. The reduced binding of FUBP1 to risk allele C defines the genomic architecture contributing to the SOX17-dependent genetic susceptibility of PAH. The downregulation of FUBP1-SOX17 by hypoxia results in endothelial dysfunction, contributing to the acquired pathogenesis of PAH. These findings identify a novel role of FUBP1 in the functional regulation of SOX17 locus and elucidating a pathogenic mechanism that combines the acquired PAH-triggering factors and altered genetic susceptibility.

SOX17 - Associated Pulmonary Hypertension in Children: A Distinct Developmental and Clinical Syndrome

SOX17 is a Critical Factor in Maintaining Endothelial Function in Pulmonary Hypertension by an Exosome‐Mediated Autocrine Manner

SOX17 Loss-of-Function Mutation Underlying Familial Pulmonary Arterial Hypertension.

Early identification of SOX17 deficiency in infants to guide management of heritable pulmonary arterial hypertension using PDA stent to create reverse Potts shunt physiology

Genes in pediatric pulmonary arterial hypertension and the most promising BMPR2 gene therapy

E2F1 Mediates SOX17 Deficiency–Induced Pulmonary Hypertension

Abstract 14257: Endothelial SOX17 Deficiency Induces Pulmonary Arterial Hypertension

Identification of a Novel Mutation in the BMPR2 Gene in a Pulmonary Arterial Hypertension Patient Using Next‐generation Sequencing

Association between Genotype, Presentation, and Outcome in Childhood Idiopathic and Hereditary Pulmonary Arterial Hypertension

E2F1/BRD4 Signaling Mediates SOX17 Deficiency Induced Pulmonary Hypertension

Abstract 13304: Sox17 Deficiency Induces Pulmonary Hypertension Through E2F1/BRD4 Signaling

Abstract P1108: Functional Genomics Analysis Of Sox17 Locus To Define The Pathogenic Role Of FUBP1 In Pulmonary Arterial Hypertension

Exome Sequencing Identifies Rare Variants in Novel Candidate Genes Associated with Pulmonary Atresia

SOX17 Prevents Endothelial-Mesenchymal Transition of Pulmonary Arterial Endothelial Cells in Pulmonary Hypertension through Mediating TGF-β/Smad2/3 Signaling

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension

Characteristics, Long-term Survival, and Risk Assessment of Pediatric Pulmonary Arterial Hypertension in China Insights From a National Multicenter Prospective Registry

Role of Forkhead box F1 in the Pathobiology of Pulmonary Arterial Hypertension

Clinical characteristics and therapeutic outcomes of pulmonary arterial hypertension secondary to congenital portosystemic shunts

Phenotype characterisation of TBX4 mutation and deletion carriers with neonatal and paediatric pulmonary hypertension

Light at the ENDothelium-role of Sox17 and Runx1 in endothelial dysfunction and pulmonary arterial hypertension

Characteristics, Long-term Survival, and Risk Assessment of Pediatric Pulmonary Arterial Hypertension in China